Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$36.95 USD

36.95
1,964,098

+0.37 (1.01%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $36.96 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Medtronic Partners Foxconn to Scale Up Ventilator Production

by Zacks Equity Research

Medtronic (MDT) enters into a partnership with Foxconn with an aim of providing 10,000 PB560 ventilators in the United States over the next year amid the pandemic-led surge in demand for the same.

Zacks Equity Research

Henry Schein Dental Software Arm May Rebound Despite Pandemic

by Zacks Equity Research

Henry Schein (HSIC) also seems to be upbeat about its dental technology business, Henry Schein One.

Zacks Equity Research

Walgreens' Retail Pharmacy Grows Amid Coronavirus Crisis

by Zacks Equity Research

Walgreens' (WBA) tie-ups with Alphabet's life sciences and healthcare segment, Verily on multiple projects related to chronic ailments buoy optimism.

Zacks Equity Research

Illumina Takes Over BlueBee, Fortifies NGS Data Processing

by Zacks Equity Research

With this acquisition, the cloud capability of BlueBee's platform will help Illumina (ILMN) to lower the cost of storing, sharing and managing the company's huge volumes of genomic data.

Zacks Equity Research

Tandem Diabetes Gets Expanded Indication for Insulin Pump

by Zacks Equity Research

Tandem Diabetes (TNDM) receives clearance for expanded indication for pediatric use of t:slim X2 insulin pump with Control-IQ, paving the way for simpler diabetes management in younger patient pool.

Zacks Equity Research

Myriad Genetics' Prolaris Receives Favorable Coverage Policies

by Zacks Equity Research

Myriad Genetics (MYGN) paves the way for bringing more prostate cancer patients under the purview of Prolaris testing through their health plan.

Zacks Equity Research

Medtronic Gets CE Mark for Micra AV Pacer to Treat AV Block

by Zacks Equity Research

With the approval of Medtronic's (MDT) Micra AV, more pacemaker patients will be eligible for a new treatment option.

Zacks Equity Research

Abbott's Libre 2 iCGM Gets FDA Nod to Better Manage Diabetes

by Zacks Equity Research

Abbott's (ABT) FDA-cleared FreeStyle Libre 2 iCGM is the only available system to continuously transmit glucose data with real-time alarms.

Zacks Equity Research

STERIS (STE) Segmental Growth Robust Amid Coronavirus Woes

by Zacks Equity Research

As a major landmark for STERIS (STE), in fiscal 2020, the company joined the coveted S&P 500 Index.

Zacks Equity Research

Here's Why You Should Hold on to Hill-Rom (HRC) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Hill-Rom (HRC) on robust domestic growth as well as solid second-quarter of fiscal 2020 results.